FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A ...

A study conducted in The Netherlands showed that nearly 45% of patients with bladder cancer had pathologic upstaging after radical cystectomy. Discrepancies between clinical and pathologic staging of ...

Eighty-seven patients with completely resected pathologic stage II NSGCT were treated with adjuvant EP chemotherapy. Adjuvant EP consisted of two cycles of etoposide (100 mg/m 2) plus cisplatin (20 mg ...

SINGAPORE — Proposed updates to the tumor-node-metastasis (TNM) classification for lung cancer will affect the way patients are staged, experts say. The updates for the 9th Edition of the TNM ...

Highest reported pathologic complete response rate seen in a phase 3 registrational trial for HER2 positive early breast cancer with favorable safety profile versus standard treatment DESTINY-Breast11 ...

Having high levels of the biomarker carbohydrate antigen 19-9 before surgery is associated with bladder cancer recurrence among patients who undergo radical cystectomy. In patients with bladder cancer ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Positive results from the DESTINY-Breast11 phase 3 trial showed ENHERTU ® (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab ...